Zero Candida Technologies Moves Towards TSX Venture Listing
Zero Candida Technologies Inc. is excited to share that it has submitted its application to list its common shares on the TSX Venture Exchange (TSXV). The Toronto-based company specializes in innovative medical technology designed to combat Candidiasis using an AI-driven device. This application marks a significant milestone for the company as it continues to develop its groundbreaking approach in women's health.
Recent Developments and Corporate Changes
Previously known as 1319743 B.C. Ltd., the company has recently completed a critical acquisition of Zero Candida Ltd., an Israeli private firm renowned for its revolutionary treatment solutions. This acquisition has resulted in a name change to Zero Candida Technologies Inc., along with a significant restructuring of its share capital. The company executed a share split to enhance liquidity for its existing and prospective investors.
Key Appointments in Management
With the successful acquisition, Zero Candida has appointed a new board of directors, including Eli Ben-Haroosh and Asher Holzer among others. This restructuring aims to steer the company effectively in its mission to push the boundaries of medical technology in women’s health.
Leadership Vision for the Future
Eli Ben-Haroosh, the company's Chief Executive Officer, emphasized the groundbreaking potential of their AI-powered device, which not only treats Candidiasis but also transmits medical data to doctors via Wi-Fi. The goal is to embark on pre-clinical studies and potentially submit results to regulatory bodies by 2025. The company envisions establishing collaborations with hospitals and academic institutions globally to enhance its research and development efforts.
Innovation in Women's Health Technology
Zero Candida’s innovative technology synergizes a specialized therapy light with a drug delivery system, aiming for optimal treatment of Candidiasis. Preliminary studies demonstrate a phenomenal 99.9999% elimination rate of Candidiasis within three days of treatment. The company anticipates advancing its technology to secure FDA approval as a Class II De Novo device.
Progress in Clinical Trials
In the last few months, the company has made substantial advancements in its product design and safety studies. Recent reports from pre-clinical safety tests indicated no safety issues, reinforcing the viability of their technology for future applications. Their commitment to delivering a safe, effective solution positions them as a potential leader in the medical technology field.
Anticipated Trading Timeline
Pending final approval from the TSXV, Zero Candida expects that its common shares will begin trading shortly. This is a promising development for investors looking to engage with an innovative company redefining treatment options in women's health. However, the final decision is contingent on the satisfaction of all regulatory requirements specifics laid out by the TSXV.
About Zero Candida Technologies
Zero Candida Technologies focuses on developing patented solutions aimed at women's health challenges. With its pilot prototype completed in 2022, the company immediately commenced laboratory tests, progressing through pre-clinical studies with positive outcomes. Their unique approach provides an integrated device that combines treatment with data analysis to improve patient outcomes.
Frequently Asked Questions
What is Zero Candida Technologies Inc. known for?
Zero Candida Technologies is known for developing an AI-driven medical device designed to treat Candidiasis and relay treatment data to healthcare providers.
How has the company changed recently?
The company recently completed an acquisition of Zero Candida Ltd., leading to a name change and significant restructuring of its share capital.
What advancements has Zero Candida made in its technology?
The company has developed a prototype that has successfully demonstrated remarkable treatment efficacy in pre-clinical studies.
When does Zero Candida expect to start trading on the TSXV?
While a specific date has not been confirmed, the company anticipates trading to commence soon upon receiving final approval from the TSXV.
What are the leadership’s long-term goals?
The leadership aims to advance women's health through innovative technological developments and regulatory approvals, enhancing collaboration in healthcare settings.
